Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD 02 December 2016 GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta®(fluticasone furoate / vilanterol 100/25 mcg) for the relief [..]
IBM and Pfizer Collaboration to Accelerate Immuno-oncology Research with Watson for Drug Discovery Collaboration combines IBM Watson’s cognitive computing capabilities with Pfizer’s scientific knowledge to help scientists generate meaningful insights December 2, 2016 ARMONK, N.Y. and NEW YORK, Dec. 1, 2016 /PRNewswire/ — IBM (NYSE: IBM) Watson Health and [..]
LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint By: Pfizer News December 2, 2016 Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four [..]
New Chemical Tool to Control Inflammation With the Help of UV Light By: Krishna Ramanujan See Also: Cornell News Black light does more than make posters glow. Cornell researchers have developed a chemical tool to control inflammation that is activated by ultraviolet (UV) light. The method will allow scientists to [..]
Copyright © 2024 | WordPress Theme by MH Themes